Cargando…
Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects
The monkeypox disease (MPX) outbreak of 2022 has been reported in more than one hundred countries and is becoming a global concern. Unfortunately, only a few treatments, such as tecovirimat (TCV), are available against MPX. Brincidofovir (BCV) is a United States Food and Drug Administration (USFDA)-...
Autores principales: | Imran, Mohd., Alshammari, Mohammed Kanan, Arora, Mandeep Kumar, Dubey, Amit Kumar, Das, Sabya Sachi, Kamal, Mehnaz, Alqahtani, Abdulaziz Saad Abdulrahman, Sahloly, Mohammed Ahmed Yahya, Alshammari, Ahmed Hammad, Alhomam, Hessah Mohammed, Mahzari, Aeshah Mousa, Abida, Rabaan, Ali A., Dzinamarira, Tafadzwa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953536/ https://www.ncbi.nlm.nih.gov/pubmed/36830816 http://dx.doi.org/10.3390/biomedicines11020278 |
Ejemplares similares
-
The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature
por: Imran, Mohd, et al.
Publicado: (2022) -
Nigella sativa L. and COVID-19: A Glance at The Anti-COVID-19 Chemical Constituents, Clinical Trials, Inventions, and Patent Literature
por: Imran, Mohd, et al.
Publicado: (2022) -
Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature
por: Alshammari, Mohammed Kanan, et al.
Publicado: (2022) -
A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak
por: Almehmadi, Mazen, et al.
Publicado: (2022) -
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
por: Imran, Mohd., et al.
Publicado: (2021)